Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

NCT00299494 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

119

Enrollment

INDUSTRY

Sponsor class

Conditions

B-Cell Lymphoma

Interventions

DRUG: inotuzumab ozogamicin
DRUG: inotuzumab ozogamicin
DRUG: inotuzumab ozogamicin
DRUG: Rituximab

Sponsor

Pfizer

Collaborators

[object Object]